title: Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome.
abstract: BACKGROUND
  The presence of antiphospholipid antibodies (aPL) is associated with infections, drugs and autoimmune disorders. Those antibodies are also detected in approximately 5-20% of the healthy population. The presence of aPL can lead to the occurrence of thrombotic events or abortion, which define the antiphospholipid syndrome (APS).
  
  
  OBJECTIVE
  To evaluate the potential role of aPL in diagnosing APS in patients with localized scleroderma (LoS).
  
  
  METHODS
  Serum samples from 45 patients with various forms of LoS were examined. They were screened with the commercially-available immunodot assay Anti-Phospholipid 10 Dot (GA Generic Assays GmbH, Dahlewitz, Germany). A number of clinical and laboratory parameters, especially APS symptoms, were assessed in patients with positive aPL: arterial and venous thrombotic events, obstetric complications, thrombocytopenia and neurological symptoms.
  
  
  RESULTS
  THE FOLLOWING PROFILE OF APL IGG OR IGM WAS OBTAINED FROM PATIENTS WITH LOS: cardiolipin 15/45, phosphatidic acid 41/45, phosphatidyl-choline 0/45, -ethanolamine 6/45, -glycerole 1/45 (patient with Lyme disease), -inositol 7/45, -serine 14/45, annexin V 34/45, β2GPI 21/45, prothrombin 30/45. Antiphospholipid antibodies profile screening in these individuals revealed two cases of suspected secondary laboratory APS. However, no such clinical and laboratory parameters were found in other LoS patients with positive aPL. Similarly, no association was found between the presence of aPL and either thrombotic events or other APS symptoms.
  
  
  CONCLUSIONS
  Antiphospholipid antibodies are commonly found in patients with LoS but the exact role of these antibodies remains unclear. Clinical manifestations of APS are not frequently seen during LoS.
authors.affiliation: Department of Dermatology, Medical University of Silesia, Katowice, Poland. Head of Department: Prof. Ligia Brzezińska-Wcisło MD, PhD.
authors.forename: Anna
authors.initials: A
authors.lastname: Lis-Święty
authors.affiliation: Department of Dermatology, Medical University of Silesia, Katowice, Poland. Head of Department: Prof. Ligia Brzezińska-Wcisło MD, PhD.
authors.forename: Ligia
authors.initials: L
authors.lastname: Brzezińska-Wcisło
authors.affiliation: Department of Dermatology, Medical University of Silesia, Katowice, Poland. Head of Department: Prof. Ligia Brzezińska-Wcisło MD, PhD.
authors.forename: Hubert
authors.initials: H
authors.lastname: Arasiewicz
authors.affiliation: Department of Dermatology, Medical University of Silesia, Katowice, Poland. Head of Department: Prof. Ligia Brzezińska-Wcisło MD, PhD.
authors.forename: Beata
authors.initials: B
authors.lastname: Bergler-Czop
keywords: antiphospholipid antibodies; antiphospholipid syndrome; localized scleroderma
references.citation: Autoimmun Rev. 2012 Dec;12(2):230-4
references.pmid: 22796282
references.citation: Postepy Dermatol Alergol. 2013 Dec;30(6):337-42
references.pmid: 24493995
references.citation: Immunol Res. 2013 Jul;56(2-3):432-8
references.pmid: 23572433
references.citation: Ann Rheum Dis. 2003 Aug;62(8):771-4
references.pmid: 12860735
references.citation: Pneumonol Alergol Pol. 2009;77(5):460-8
references.pmid: 19890826
references.citation: Dermatology. 1994;189(3):304-7
references.pmid: 7949491
references.citation: Medicina (B Aires). 1998;58(1):67-77
references.pmid: 9674212
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:455-9
references.pmid: 23233619
references.citation: Thromb Res. 2012 Dec;130(6):914-8
references.pmid: 23079292
references.citation: Rheumatology (Oxford). 2005 Mar;44(3):274-9
references.pmid: 15561734
references.citation: Arthritis Res Ther. 2011 Jul 21;13(4):R118
references.pmid: 21777436
references.citation: Rheumatology (Oxford). 2013 Aug;52(8):1358-67
references.pmid: 23502076
references.citation: Arch Med Sci. 2012 Nov 9;8(5):819-25
references.pmid: 23185190
references.citation: Curr Rheumatol Rep. 2013 Feb;15(2):308
references.pmid: 23307579
references.citation: Egypt J Immunol. 2009;16(1):1-8
references.pmid: 20726317
references.citation: Autoimmun Rev. 2011 Jul;10(9):553-8
references.pmid: 21527362
references.citation: J Neuroinflammation. 2009 Jan 20;6:3
references.pmid: 19154576
references.citation: Clin Exp Immunol. 2005 Apr;140(1):173-80
references.pmid: 15762889
references.citation: Rheumatology (Oxford). 2006 May;45(5):614-20
references.pmid: 16368732
references.citation: J Eur Acad Dermatol Venereol. 2001 Jan;15(1):9-10
references.pmid: 11451343
references.citation: Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):387-92
references.pmid: 18547483
references.citation: Arch Dermatol. 2009 May;145(5):545-50
references.pmid: 19451498
references.citation: Clin Exp Rheumatol. 2006 Jan-Feb;24(1):19-24
references.pmid: 16539814